(21 days)
Not Found
Not Found
No
The summary describes a mechanical stent and delivery system with no mention of AI/ML capabilities or related performance metrics.
Yes
The device is intended for the palliation of malignant neoplasms in the biliary tree, which is a therapeutic purpose.
No
Explanation: The device description clearly states it is a self-expanding stent system intended for palliation of malignant neoplasms in the biliary tree, which is a treatment, not a diagnostic, function.
No
The device description explicitly states it is a "system consisting of a self-expanding, open mesh, nitinol stent preloaded onto a sheathed delivery catheter," which are physical hardware components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is "palliation of malignant neoplasms in the biliary tree." This describes a therapeutic intervention performed within the body to treat a disease.
- Device Description: The device is a "self-expanding, open mesh, nitinol stent preloaded onto a sheathed delivery catheter." This is a physical implantable device used to open up a blocked passage.
- Mechanism of Action: The device works by being delivered to a stricture site and expanding to conform to the inner lumen of the biliary duct, physically opening it.
IVD devices are used in vitro (outside the body) to examine specimens (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening. This device is used in vivo (within the body) for treatment.
N/A
Intended Use / Indications for Use
The Cordis S.M.A.R.T.TM Nitinol Stent Transhepatic Biliary System is intended for use in the palliation of malignant neoplasms in the biliary tree.
Product codes (comma separated list FDA assigned to the subject device)
78 FGE
Device Description
The Cordis S.M.A.R.T.TM Nitinol Stent Transhepatic Biliary System is a system consisting of a self-expanding, open mesh, nitinol stent preloaded onto a sheathed delivery catheter. The delivery system is designed to deliver the stent to the stricture site via transhepatic access. Once positioned at the stricture site, the sheath is withdrawn and the stent is released. Upon release, the stent expands and conforms to the inner lumen of the biliary duct.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
biliary tree, biliary duct
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The equivalence was substantially equivalent to the predicate device. confirmed through pre-clinical testing.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
• Cordis S.M.A.R.T.TM Nitinol Stent Transhepatic Biliary System
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 876.5010 Biliary catheter and accessories.
(a)
Identification. A biliary catheter and accessories is a tubular flexible device used for temporary or prolonged drainage of the biliary tract, for splinting of the bile duct during healing, or for preventing stricture of the bile duct. This generic type of device may include a bile collecting bag that is attached to the biliary catheter by a connector and fastened to the patient with a strap.(b)
Classification. Class II (special controls). The device, when it is a bile collecting bag or a surgical biliary catheter that does not include a balloon component, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
0
Page _ 1 of 1
510(k) Number (if known): K994068
Device Name:Cordis S.M.A.R.T.TM Nitinol Stent Transhepatic Billiary System__
FDA's Statement of the Indications For Use for device:
The Cordis S.M.A.R.T.™ Nitinol Stent Transhepatic Biliary System is intended for use in the palliation of malignant neoplasms in the biliary tree.
ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ
Over-The-Counter Use__________________________________________________________________________________________________________________________________________________________ Prescription Use______________________________________________________________________________________________________________________________________________________________ OR (Per 21 CFR 801.109)
1
""""
DEC 2 3 1999
Attachment 4
Summary of Safety and Effectiveness
| General Provisions | The name of the device is: |
|---|---|
| -------------------- | ---------------------------- |
| Proprietary Name | Common or Usual Name |
|---|---|
| Cordis S.M.A.R.T. TM Nitinol Stent | |
| Transhepatic Biliary System | Biliary Stent |
| Name of
Predicate
| Devices | The device is substantially equivalent to: |
|---|---|
| • Cordis S.M.A.R.T. TM Nitinol Stent Transhepatic Biliary System | |
| Classification | Class II. |
| Performance | |
| Standards | Performance standards have not been established by the FDA under section |
| 514 of the Food, Drug and Cosmetic Act. | |
| Indications for | |
| Use | The Cordis S.M.A.R.T. TM Nitinol Stent Transhepatic Biliary System is |
| intended for use in the palliation of malignant neoplasms in the biliary tree. | |
| Device | |
| Description | The Cordis S.M.A.R.T. TM Nitinol Stent Transhepatic Biliary System is a |
| system consisting of a self-expanding, open mesh, nitinol stent preloaded onto | |
| a sheathed delivery catheter. The delivery system is designed to deliver the | |
| stent to the stricture site via transhepatic access. Once positioned at the | |
| stricture site, the sheath is withdrawn and the stent is released. Upon release, | |
| the stent expands and conforms to the inner lumen of the biliary duct. | |
| Biocompatibility | All materials used in the Cordis S.M.A.R.T. TM Nitinol Stent Transhepatic |
| Biliary System are biocompatible. |
Continued on next page
2
Summary of Substantial Equivalence
The Cordis S.M.A.R.T.TM Nitinol Stent Transhepatic Biliary System is The equivalence was substantially equivalent to the predicate device. confirmed through pre-clinical testing.
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image is a black and white circular seal. The seal contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter of the circle. Inside the circle is a stylized image of an eagle with three curved lines representing its wings and a wavy line representing its body.
Public Health Service
DEC 2 3 1999
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Ms. Elena S. Jugo, R.A.C. Manager, Regulatory Affairs Cordis Corporation P.O. Box 025700 Miami, FL 33102-5700
K994068 Rc:
Cordis S.M.A.R.T.TM Nitinol Stent Transhepatic Biliary System Regulatory Class: II 21 CFR 876.5010 Product Code: 78 FGE Dated: December 1, 1999 Received: December 2, 1999
Dear Ms. Jugo:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
The Office of Device Evaluation has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling:
The safety and effectiveness of this device for use in the vascular system have not been established.
Furthermore, the indication for biliary use must be prominently displayed in all labeling, including pouch, box, and carton labels, instructions for use, and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print.
4
Page 2 - Ms. Elena S. Jugo
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations ( recting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification if the limitation statement above is added to your labeling, as described.
Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling.
If you desire specific information about the application of other labeling requirements to your device (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4616. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
David W. Brinkley, MD, MPH
David W. Feigal, Jr., M.D., M.P.H. Acting Director Office of Device Evaluation Center for Devices and Radiological Health
Enclosure